drugset / Trial / NCT04017377
VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer
SequentialOpen-labelTreatment
Summary
This is a single arm, open-lable Phase I clinical trial. Eligible patients will have Histologically proven stage IB2-IVA cervical cancer. We hypothesize that Nab-paclitaxel in combination with cisplatin and radiotherapy may have anti-tumor activity in patients with cervical cancer. Nab-paclitaxel has not previously been combined with conventional RT-CT to treat cervical cancer.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2020-06-15
- Completion
- 2020-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 10 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 70 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | — |